Details of the Drug

General Information of Drug (ID: DMB4HCT)

Drug Name
Sparfloxacin
Synonyms
Esparfloxacino; SPFX; Spara; Sparfloxacine; Sparfloxacinum; Zagam; AT 4140; CP 103826; PD 131501; PD131501; AT-4140; CP-103826; DRG-0143; Esparfloxacino [INN-Spanish]; Liposome-encapsulated sparfloxacin; PD 1315-1; PD-131501; RP-64206; Respipac (TN); Sparfloxacin & RU 40555; Sparfloxacine [INN-French]; Sparfloxacinum [INN-Latin]; Zagam (TN); Sparfloxacin, cis-isomer; Sparfloxacin (JAN/USAN/INN); Sparfloxacin [USAN:BAN:INN:JAN]; Cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; (cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Mycoplasma pneumoniae pneumonia N.A. Approved [2]
Pneumonia CA40 Approved [2]
Pneumonia caused by chlamydia N.A. Investigative [2]
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 392.4
Logarithm of the Partition Coefficient (xlogp) 0.1
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
92% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 2.7 mL/min/kg [5]
Elimination
10% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 20 hours [5]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 8.486 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.55% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.9 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 1.1 mg/mL [3]
Chemical Identifiers
Formula
C19H22F2N4O3
IUPAC Name
5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
Canonical SMILES
C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F
InChI
InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+
InChIKey
DZZWHBIBMUVIIW-DTORHVGOSA-N
Cross-matching ID
PubChem CID
60464
ChEBI ID
CHEBI:9212
CAS Number
110871-86-8
DrugBank ID
DB01208
TTD ID
D0K6GZ
VARIDT ID
DR00791
ACDINA ID
D01439
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU ; GYRB_STAAU Modulator [7]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sparfloxacin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Ivosidenib. Acute myeloid leukaemia [2A60] [9]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Midostaurin. Acute myeloid leukaemia [2A60] [10]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Arn-509. Acute myeloid leukaemia [2A60] [10]
Gilteritinib DMTI0ZO Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Gilteritinib. Acute myeloid leukaemia [2A60] [10]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Oliceridine. Acute pain [MG31] [9]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Sparfloxacin and Ivabradine. Angina pectoris [BA40] [11]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Dronedarone. Angina pectoris [BA40] [12]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [10]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Posaconazole. Aspergillosis [1F20] [10]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Sparfloxacin and Pirbuterol. Asthma [CA23] [13]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [10]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Retigabine. Behcet disease [4A62] [9]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Eribulin. Breast cancer [2C60-2C6Y] [10]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Lapatinib. Breast cancer [2C60-2C6Y] [10]
Thiotepa DMIZKOP Minor Decreased absorption of Sparfloxacin due to intestinal mucosa variation caused by Thiotepa. Breast cancer [2C60-2C6Y] [14]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [9]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Sparfloxacin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [15]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Sparfloxacin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [13]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Sparfloxacin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [15]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Sparfloxacin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [15]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Sevoflurane. Corneal disease [9A76-9A78] [10]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Pasireotide. Cushing syndrome [5A70] [10]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Osilodrostat. Cushing syndrome [5A70] [9]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Clomipramine. Depression [6A70-6A7Z] [10]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [10]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Deutetrabenazine. Dystonic disorder [8A02] [10]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Ingrezza. Dystonic disorder [8A02] [10]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Solifenacin. Functional bladder disorder [GC50] [10]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [10]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [9]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [10]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [9]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [10]
Bempedoic acid DM1CI9R Major Increased risk of tendinitis/tendon rupture by the combination of Sparfloxacin and Bempedoic acid. Hyper-lipoproteinaemia [5C80] [16]
Iron DMAP8MV Moderate Decreased absorption of Sparfloxacin due to formation of complexes caused by Iron. Iron deficiency anaemia [3A00] [17]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Sparfloxacin and Polyethylene glycol. Irritable bowel syndrome [DD91] [18]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Crizotinib. Lung cancer [2C25] [10]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Ceritinib. Lung cancer [2C25] [10]
Lurbinectedin DMEFRTZ Minor Decreased absorption of Sparfloxacin due to intestinal mucosa variation caused by Lurbinectedin. Lung cancer [2C25] [14]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Osimertinib. Lung cancer [2C25] [10]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Selpercatinib. Lung cancer [2C25] [9]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Lumefantrine. Malaria [1F40-1F45] [9]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Hydroxychloroquine. Malaria [1F40-1F45] [10]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [10]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Vemurafenib. Melanoma [2C30] [10]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and LGX818. Melanoma [2C30] [10]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Panobinostat. Multiple myeloma [2A83] [10]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Sparfloxacin and Fingolimod. Multiple sclerosis [8A40] [12]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Ozanimod. Multiple sclerosis [8A40] [10]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Romidepsin. Mycosis fungoides [2B01] [9]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Nilotinib. Myeloproliferative neoplasm [2A20] [10]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Dasatinib. Myeloproliferative neoplasm [2A20] [10]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Entrectinib. Non-small cell lung cancer [2C25] [9]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Lofexidine. Opioid use disorder [6C43] [10]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Rucaparib. Ovarian cancer [2C73] [10]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Triclabendazole. Parasitic worm infestation [1F90] [9]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Pimavanserin. Parkinsonism [8A00] [10]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Macimorelin. Pituitary gland disorder [5A60-5A61] [19]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Lefamulin. Pneumonia [CA40] [9]
Choline salicylate DM8P137 Moderate Additive CNS stimulant effects by the combination of Sparfloxacin and Choline salicylate. Postoperative inflammation [1A00-CA43] [20]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Degarelix. Prostate cancer [2C82] [10]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Sparfloxacin and ABIRATERONE. Prostate cancer [2C82] [10]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Enzalutamide. Prostate cancer [2C82] [10]
Salsalate DM13P4C Moderate Additive CNS stimulant effects by the combination of Sparfloxacin and Salsalate. Rheumatoid arthritis [FA20] [21]
Dexamethasone DMMWZET Major Increased risk of tendinitis/tendon rupture by the combination of Sparfloxacin and Dexamethasone. Rheumatoid arthritis [FA20] [22]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Quetiapine. Schizophrenia [6A20] [10]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Sparfloxacin and Aripiprazole. Schizophrenia [6A20] [23]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Iloperidone. Schizophrenia [6A20] [10]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Paliperidone. Schizophrenia [6A20] [10]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Amisulpride. Schizophrenia [6A20] [10]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Asenapine. Schizophrenia [6A20] [10]
Docetaxel DMDI269 Minor Decreased absorption of Sparfloxacin due to intestinal mucosa variation caused by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [14]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Sparfloxacin and LEE011. Solid tumour/cancer [2A00-2F9Z] [10]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [10]
Taxol DMUOT9V Minor Decreased absorption of Sparfloxacin due to intestinal mucosa variation caused by Taxol. Solid tumour/cancer [2A00-2F9Z] [14]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Pitolisant. Somnolence [MG42] [10]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [10]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Lenvatinib. Thyroid cancer [2D10] [10]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Sparfloxacin and Cabozantinib. Thyroid cancer [2D10] [10]
⏷ Show the Full List of 79 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Magnesium stearate E00208 11177 lubricant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Hydroxyethyl cellulose E00700 Not Available Coating agent; Suspending agent; Binding agent; Viscosity-controlling agent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sparfloxacin 200mg tablet 200mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020677.
2 Sparfloxacin FDA Label
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
9 Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996): 350-1. [PMID: 8781892]
10 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12 Canadian Pharmacists Association.
13 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
14 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
15 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
16 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
17 Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
18 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
19 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
20 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
21 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
22 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
23 Cerner Multum, Inc. "Australian Product Information.".